Drug-drug interactions of new active substances: mibefradil example.
about
Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channelsPharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450sApplication of mechanism-based CYP inhibition for predicting drug-drug interactions.Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin.T-type calcium channels inhibitors: a patent review.Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.Development of CYP3A4 inhibition models: comparisons of machine-learning techniques and molecular descriptors.Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies.Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.Implications of inter-correlation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.Single concentration loss of activity assay provides an improved assessment of drug-drug interaction risk compared to IC50-shift.
P2860
Q30437204-1DA7B551-4039-4828-8B02-1BD35290A570Q35048422-3FC60F98-0679-452E-B0C3-4AD49EBFBBBAQ35825950-D0C85F16-40B5-4D34-935B-6054F37BBFA6Q36629237-0DE997EF-BF85-4725-A819-D0D88F149CBFQ36871056-29FB2372-E162-4605-A639-5F9E41D5CD4BQ36872144-44F7FAE3-FC12-4421-BB62-0AB36A14090FQ37494640-EBA6B5F5-3B5B-44A3-B14B-6693B124FA89Q37559546-FCFC5CEA-DDA2-4AEA-A6BC-AACB1D0870A2Q37810605-0F7F9FD6-31A6-4D51-BA99-49020F2DBFA4Q42104298-B06179F3-4A32-4724-9CF5-16CC7F7E1137Q45966472-B178DDC5-3BC5-4163-8B02-8CBCCD860817Q47161371-86281E2A-D90B-4BAF-B9C6-E47612AD6503Q47267937-20F89F8C-5A9C-45EC-8D0F-9C54C3716D31Q48142540-3C95938A-C542-4F51-96B9-D23EA6473BCDQ53155407-83665E42-CAAF-4570-8B75-1B551C3A8BA9
P2860
Drug-drug interactions of new active substances: mibefradil example.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Drug-drug interactions of new active substances: mibefradil example.
@ast
Drug-drug interactions of new active substances: mibefradil example.
@en
type
label
Drug-drug interactions of new active substances: mibefradil example.
@ast
Drug-drug interactions of new active substances: mibefradil example.
@en
prefLabel
Drug-drug interactions of new active substances: mibefradil example.
@ast
Drug-drug interactions of new active substances: mibefradil example.
@en
P2093
P356
P1476
Drug-drug interactions of new active substances: mibefradil example.
@en
P2093
J C Krayenbühl
M Kondo-Oestreicher
P2888
P304
P356
10.1007/S002280050673
P577
1999-10-01T00:00:00Z
P6179
1004101792